Current Advances in Osteosarcoma

This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new editionis both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma.

Autorentext

Eugenie S. Kleinerman, holds the Mary V. and John A. Reilly Distinguished Chair, and is currently Professor at the University of Texas MD Anderson Cancer Center in the Departments of Pediatrics Research and Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particular osteosarcoma, and for pioneering the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for patients with newly diagnosed osteosarcoma or unresponsive relapsed osteosarcoma lung metastases. Her current research interests include developing novel ways to treat sarcoma patients by identifying new therapeutic targets, the properties that influence metastases, the efficacy of dendritic cell vaccines with and without checkpoint inhibitors for osteosarcoma lung metastases, how tumor vessels are formed in Ewing sarcoma and the use of exercise interventions to mitigate chemotherapy-induced cardiotoxicity.

Richard Gorlick, is currently the Mosbacher Pediatrics Chair of the Department of Pediatrics Patient Care, and Division Head of Pediatrics at the University of Texas MD Anderson Cancer Center. Dr. Gorlick is an internationally recognized expert in pediatric oncology and hematology, whose research and clinical work have focused on sarcomas, tumors that grow in connective tissues including bones, muscles, tendons and cartilage, understanding the mechanisms behind the development and progression of osteosarcoma, as well as targeted therapies and new drugs for childhood cancers.

Inhalt

1Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective

Part 1: Surgical Considerations and Outcomes

2Limb Salvage and Reconstruction Options in Osteosarcoma

3Advances in the functional assessment of patients with sarcoma

Part II: Novel Therapeutic Approaches Based on Biology 4Radiopharmaceuticals for Treatment of Osteosarcoma

5HER-2 Targeted Therapy in Osteosarcoma

6Aerosolized Chemotherapy for Osteosarcoma

7The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma

8Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease 9Using liquid biopsy in the treatment of patient with osteosarcoma

Part III: Novel Immunotherapeutic Approaches

10Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020's

11Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma

12Natural Killer Cell Immunotherapy for Osteosarcoma

13Nanocapsule delivery of IL-12

14Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy

Part IV: Survivorship and Late Effects

Editorial Comments on late effects

15Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention

16Exercise and Physical Activity in Patients with Osteosarcoma and Survivors

Index